New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
32nd Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 14 at 10:30 am; not all presentations may be webcasted. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
November 19, 2015
11:01 EDTHNTHealth Net reaches new agreement covering Tucson-area providers
Subscribe for More Information
10:58 EDTCIAnalysts say possible exchange exit positive for battered UnitedHealth
The shares of health insurer UnitedHealth (UNH) and a number of other companies in the sector are falling after the Dow member lowered its fiscal 2015 profit guidance, citing weakness in individual health insurance policies it markets through exchanges. WHAT'S NEW: UnitedHealth lowered its fiscal 2015 earnings per share guidance to $6 from $6.25-$6.35. Analysts' consensus estimate was $6.31. The company identified policies sold to individuals through exchanges as the culprit. UnitedHealth said it expects to lose 26c per share on these policies in 2015 and 2016. The insurer stated that its other businesses were performing in-line with expectations and showing strength. UnitedHealth said it has pulled back on its marketing efforts for individual exchange products in 2016 and indicated that it would consider offering fewer individual policies through exchanges in 2017. UnitedHealth provided fiscal 2016 EPS guidance of $7.10-$7.30, versus the consensus outlook of $7.28. ANALYST REACTION: Any weakness in UnitedHealth and other health insurers today on the news from UnitedHealth creates a strong buying opportunity, Leerink Swann analyst Ana Gupte wrote in a note to investors today. The government will either reform the exchanges to make them more profitable for the insurers or they will exit the market, Gupte predicted. Moreover, the downside risk for health insurers Aetna (AET), Anthem (ANTM), Humana (HUM), and Cigna (CI) from today's news are low, since their Q3 and 2016 outlooks already incorporated the negative trends cited by UnitedHealth, the analyst stated. Mizuho Securities analyst Sheryl Skolnick was more cautious, predicting that the news would "rattle" the health insurance sector. United Health is more "insulated" than its peers from the weakness of the exchanges because its exposure to the market is relatively limited and its business is more diversified than that of its peers, according to Skolnick, who kept a $150 price target and Buy rating on the stock. Meanwhile, Piper Jaffray analyst Sean Wieland says UnitedHealth reducing its exchange exposure should be accretive to shareholder value. The company's participation in exchanges is not essential to its growth strategy, according to Wieland. The issues cited for the guidance cut likely applies to all Managed Care companies, therefore UnitedHealth should outperform peers given its limited exposure to exchanges, contends Wieland, who reiterated an Overweight rating on the stock with a $149 price target. PRICE ACTION: In morning trading, UnitedHealth fell 4% to $112.49, Aetna declined 4.4% to $102.18, Humana gave back 2.4% to $167, Anthem fell 6.6% to $128.20, and Cigna slid 3.8% to $130.
10:42 EDTBSXLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
10:23 EDTHNT, CIUnitedHealth selloff on guidance presents buying opportunity, says Leerink
Subscribe for More Information
07:46 EDTHNT, CIOptions expected to be active; UNH AET ANTM CI WCG HUM HNT CNC
Subscribe for More Information
November 18, 2015
12:01 EDTBMYBristol-Myers Squibb says Opdivo data shows 'superior' overall survival
Subscribe for More Information
08:11 EDTBMYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
05:41 EDTVRTXVertex receives 2 EU approvals for Kalydeco
Vertex Pharmaceuticals announced that the European Commission has approved expansion of the indication for Kalydeco to include children ages 2 to 5 with cystic fibrosis, or CF, who have one of nine gating mutations in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene and to include people with CF ages 18 and older who have an R117H mutation. Ivacaftor was previously approved in the European Union, or EU, for use in people with CF ages 6 and older who have one of nine gating mutations. In Europe, approximately 125 children with CF ages 2 to 5 have one of the nine gating mutations included in today's approval and approximately 350 adults with CF have an R117H mutation. Vertex will now begin the country-by-country reimbursement approval processes for each new indication.
November 17, 2015
10:47 EDTBMYBristol-Myers strength attributed to sale chatter
The move higher in shares of Bristol-Myers (BMY) is being attributed by traders to chatter of a sale. The stock is up 2%, or $1.06, to $66.08 in morning trading. The unconfirmed talk has the company possibly approaching Gilead (GILD) about buyout interest. Bristol's market capitalization is just above $110B while Gilead's is just above $150B. Shares of Gilead are up 74c to $104.55.
10:00 EDTSHPGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: CF Industries (CF) upgraded to Positive at Susquehanna... ExlService (EXLS) upgraded to Buy from Neutral at BofA/Merrill... Fitbit (FIT) upgraded to Buy at BofA/Merrill... Forward Air (FWRD) upgraded to Outperform at Baird... HD Supply (HDS) upgraded to Positive from Neutral at Susquehanna... Hannover Re (HVRRY) upgraded to Overweight from Underweight at JPMorgan... Moody's (MCO) upgraded to Buy from Neutral at UBS... PRA Group (PRAA) upgraded to Strong Buy from Market Perform at Raymond James... Plum Creek Timber (PCL) upgraded to Outperform from Sector Perform at RBC Capital... Shire (SHPG) upgraded to Outperform from Market Perform at Leerink... Yandex (YNDX) upgraded to Overweight from Equal Weight at Morgan Stanley... Zayo Group (ZAYO) upgraded to Buy from Neutral at MoffettNathanson.
November 16, 2015
17:05 EDTBMYBristol-Myers announces FDA accepts for priority review sBLA for Opdivo
Bristol-Myers Squibb Company announced that the U.S. FDA has accepted for filing and priority review a supplemental Biologics License Application for Opdivo for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. The FDA previously granted Opdivo Breakthrough Therapy Designation for this indication, underscoring the critical need for new treatment options for patients with advanced RCC who have received prior therapy. The projected FDA action date is March 16, 2016.
16:53 EDTSHPGPaulson reduced stake in Valeant
Paulson & Co. gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Perrigo (PRGO), CIT Group (CIT), Precision Castparts (PCP), Cameron (CAM), and Altera (ALTR). INCREASED STAKES: Teva (TEVA), Post Holdings (POST), Starwood Hotels (HOT), LivaNova (LIVN), and Synergy Pharmaceuticals (SGYP). DECREASED STAKES: Valeant (VRX), Shire (SHPG), Whiting Petroleum (WLL), Computer Sciences (CSC), and Oasis Petroleum (OAS). LIQUIDATED STAKES: Houghton Mifflin Harcourt (HMHC), Broadcom (BRCM), and Sprint (S).
16:18 EDTSHPGShire upgraded to Outperform, price target raised to $239 at Leerink
Subscribe for More Information
16:05 EDTAMGNAmgen to present eight IMLYGIC abstracts
Subscribe for More Information
16:02 EDTSHPGShire upgraded to Outperform from Market Perform at Leerink
09:59 EDTCI, SHPGOmega bought Valeant in Q3, sold some SuneEdison
Leon Cooperman's Omega Advisors gave a quarterly update on its stakes in a filing this morning, disclosing its positions as of September 30. NEW STAKES: Pfizer (PFE), Valeant (VRX) Walgreens Boots Alliance (WBA), TerraForm Global (GLBL), Cigna (CI). INCREASED STAKES: Google Class A (GOOGL), Facebook (FB), Delta Air Lines (DAL). DECREASED STAKES: SunEdison (SUNE), Shire (SHPG), Citi (C), KAR Auction (KAR), LyondellBasell (LYB). LIQUIDATED STAKES: McKesson (MCK), 21st Century Fox (FOXA), General Motors (GM), QEP Resources (QEP), eBay (EBAY).
07:16 EDTVRTXHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).
07:00 EDTBMYBristol-Myers announces data from Phase 3 ALLY-3+ trial for Daklinza
Bristol-Myers announced late-breaking data from the Phase 3 ALLY-3+ trial investigating a regimen of Daklinza in combination with sofosbuvir and ribavirin in genotype 3 hepatitis C patients with advanced fibrosis or cirrhosis, for treatment durations of 12 and 16 weeks. This patient population is one of the most difficult to treat, among whom sustained virologic response rates, or cure, have proved harder to achieve. The results show that 100% of patients in the advanced fibrosis cohort achieved SVR12 in both the 12- and 16-week arms of the study. SVR12 rates were 83% and 89% in patients with cirrhosis in the 12- and 16-week arms, respectively.
06:02 EDTCIAnthem announces ISS recommends shareholders vote "For" Cigna acquisition
Anthem (ANTM) announced that Institutional Shareholder Services has issued a report recommending that Anthem shareholders vote to approve the issuance of Anthem stock in the proposed acquisition of Cigna (CI) at the company's special meeting of shareholders to be held on Thursday, December 3, 2015. Anthem's board unanimously recommends that Anthem shareholders vote "FOR" the proposal to issue Anthem common stock to acquire Cigna, which is necessary to complete the transaction.
06:01 EDTSHPGSynergy Pharmaceuticals appoints Gary Sender as CFO
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use